• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝 X 受体激动剂 T0901317 抑制体内外非小细胞肺癌细胞的迁移和侵袭。

Liver X receptor agonist T0901317 inhibits the migration and invasion of non-small-cell lung cancer cells in vivo and in vitro.

机构信息

The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, Jiangsu Province, China.

Research Center for Clinical Oncology.

出版信息

Anticancer Drugs. 2019 Jun;30(5):495-500. doi: 10.1097/CAD.0000000000000758.

DOI:10.1097/CAD.0000000000000758
PMID:30724772
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6485493/
Abstract

Liver X receptors are recognized as important regulators of cholesterol, fatty acid metabolism, inflammatory responses, and glucose homeostasis. The antineoplastic properties of synthetic liver X receptor (LXR) agonists (T0901317 and GW3965) have been reported in human carcinomas. Epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI) is a first-line treatment for non-small-cell lung cancer patients with EGFR mutations. We used scratch and transwell assays to analyze cell migration and invasion. We evaluated tumor migration and invasion in vitro using a fluorescent orthotopic lung cancer model. An MMP9 (mouse) enzyme-linked immunosorbent assay kit was used to measure serum MMP9 concentrations. Protein expression was identified by western blot assays. In this study, we determined the effects of T0901317 and/or an EGFR-TKI on the lung cancer cell lines A549 and HCC827-8-1 in vitro and in vivo. We confirmed that the combination of the LXR agonist T0901317 and gefitinib can inhibit the migration and invasion of lung cancer both in vivo and in vitro, and this effect was possibly achieved by the inhibition of the ERK/MAPK signaling pathway. Our study showed that the combination of the LXR agonist T0901317 and gefitinib can inhibit the migration and invasion of lung cancer both in vivo and in vitro.

摘要

肝 X 受体被认为是胆固醇、脂肪酸代谢、炎症反应和葡萄糖稳态的重要调节因子。合成肝 X 受体 (LXR) 激动剂 (T0901317 和 GW3965) 的抗肿瘤特性已在人类癌中得到报道。表皮生长因子酪氨酸激酶抑制剂 (EGFR-TKI) 是 EGFR 突变的非小细胞肺癌患者的一线治疗药物。我们使用划痕和 Transwell 分析来分析细胞迁移和侵袭。我们使用荧光原位肺癌模型评估体外肿瘤迁移和侵袭。使用 MMP9(小鼠)酶联免疫吸附测定试剂盒测量血清 MMP9 浓度。通过 Western blot 分析鉴定蛋白表达。在这项研究中,我们确定了 T0901317 和/或 EGFR-TKI 对 A549 和 HCC827-8-1 肺癌细胞系的体外和体内作用。我们证实,LXR 激动剂 T0901317 和吉非替尼的联合使用可以抑制肺癌的迁移和侵袭,无论是在体内还是体外,这种作用可能是通过抑制 ERK/MAPK 信号通路实现的。我们的研究表明,LXR 激动剂 T0901317 和吉非替尼的联合使用可以抑制肺癌的迁移和侵袭,无论是在体内还是体外。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b64/6485493/019c48702aca/cad-30-495-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b64/6485493/5ee0231c2d1d/cad-30-495-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b64/6485493/3262758916ec/cad-30-495-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b64/6485493/8b09afb6c9d6/cad-30-495-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b64/6485493/019c48702aca/cad-30-495-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b64/6485493/5ee0231c2d1d/cad-30-495-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b64/6485493/3262758916ec/cad-30-495-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b64/6485493/8b09afb6c9d6/cad-30-495-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b64/6485493/019c48702aca/cad-30-495-g005.jpg

相似文献

1
Liver X receptor agonist T0901317 inhibits the migration and invasion of non-small-cell lung cancer cells in vivo and in vitro.肝 X 受体激动剂 T0901317 抑制体内外非小细胞肺癌细胞的迁移和侵袭。
Anticancer Drugs. 2019 Jun;30(5):495-500. doi: 10.1097/CAD.0000000000000758.
2
Fucoxanthin extracted from Laminaria Japonica inhibits metastasis and enhances the sensitivity of lung cancer to Gefitinib.从裙带菜中提取的岩藻黄质可抑制肺癌转移并增强吉非替尼对肺癌的敏感性。
J Ethnopharmacol. 2021 Jan 30;265:113302. doi: 10.1016/j.jep.2020.113302. Epub 2020 Aug 26.
3
Liver X receptors agonist T0901317 downregulates matrix metalloproteinase-9 expression in non-small-cell lung cancer by repressing nuclear factor-κB.肝脏X受体激动剂T0901317通过抑制核因子κB下调非小细胞肺癌中基质金属蛋白酶-9的表达。
Anticancer Drugs. 2017 Oct;28(9):952-958. doi: 10.1097/CAD.0000000000000532.
4
A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance.一种新型 STAT3 抑制剂 W2014-S 使人类非小细胞肺癌异种移植消退,并使 EGFR-TKI 获得性耐药敏感。
Theranostics. 2021 Jan 1;11(2):824-840. doi: 10.7150/thno.49600. eCollection 2021.
5
CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo.CM082,一种新型血管生成抑制剂,增强了吉非替尼在表皮生长因子受体突变型非小细胞肺癌中的抗肿瘤活性,无论是在体外还是体内实验中。
Thorac Cancer. 2020 Jun;11(6):1566-1577. doi: 10.1111/1759-7714.13430. Epub 2020 May 5.
6
Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.环孢素A通过抑制信号转导和转录激活因子3(STAT3)使人类非小细胞肺癌细胞对吉非替尼敏感。
Cancer Lett. 2016 Aug 28;379(1):124-33. doi: 10.1016/j.canlet.2016.06.002. Epub 2016 Jun 2.
7
Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.阿帕替尼增强了表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)对具有EGFR-TKI耐药性的非小细胞肺癌的抗肿瘤活性。
Eur J Cancer. 2017 Oct;84:184-192. doi: 10.1016/j.ejca.2017.07.037. Epub 2017 Aug 17.
8
Phenethyl isothiocyanate synergistically induces apoptosis with Gefitinib in non-small cell lung cancer cells via endoplasmic reticulum stress-mediated degradation of Mcl-1.苯乙基异硫氰酸酯通过内质网应激介导的 Mcl-1 降解与吉非替尼协同诱导非小细胞肺癌细胞凋亡。
Mol Carcinog. 2020 Jun;59(6):590-603. doi: 10.1002/mc.23184. Epub 2020 Mar 18.
9
Enoxaparin sensitizes human non-small-cell lung carcinomas to gefitinib by inhibiting DOCK1 expression, vimentin phosphorylation, and Akt activation.依诺肝素通过抑制DOCK1表达、波形蛋白磷酸化和Akt激活,使人非小细胞肺癌对吉非替尼敏感。
Mol Pharmacol. 2015;87(3):378-90. doi: 10.1124/mol.114.094425. Epub 2014 Dec 8.
10
EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.EZH2 抑制剂可逆转原发性 EGFR 野生型肺癌细胞对吉非替尼的耐药性。
BMC Cancer. 2020 Dec 4;20(1):1189. doi: 10.1186/s12885-020-07667-7.

引用本文的文献

1
Implications of GPIIB-IIIA Integrin and Liver X Receptor in Platelet-Induced Compression of Ovarian Cancer Multi-Cellular Spheroids.糖蛋白IIb-IIIa整合素与肝脏X受体在血小板诱导的卵巢癌多细胞球体压缩中的作用
Cancers (Basel). 2024 Oct 19;16(20):3533. doi: 10.3390/cancers16203533.
2
Immuno-PET Imaging of EGFR with Cu-NOTA Panitumumab in Subcutaneous and Metastatic Nonsmall Cell Lung Cancer Xenografts.EGFR 免疫 PET 显像:应用 Cu-NOTA 帕尼单抗在皮下和转移性非小细胞肺癌异种移植瘤中的研究
Mol Pharm. 2024 Nov 4;21(11):5797-5806. doi: 10.1021/acs.molpharmaceut.4c00823. Epub 2024 Oct 15.
3
Cholesterol metabolism in tumor microenvironment: cancer hallmarks and therapeutic opportunities.

本文引用的文献

1
Liver X receptors constrain tumor development and metastasis dissemination in PTEN-deficient prostate cancer.肝脏X受体抑制PTEN缺陷型前列腺癌的肿瘤发展和转移扩散。
Nat Commun. 2017 Sep 5;8(1):445. doi: 10.1038/s41467-017-00508-5.
2
Liver X receptor agonist T0901317 reverses resistance of A549 human lung cancer cells to EGFR-TKI treatment.肝脏X受体激动剂T0901317可逆转A549人肺癌细胞对EGFR-TKI治疗的耐药性。
FEBS Open Bio. 2016 Dec 20;7(1):35-43. doi: 10.1002/2211-5463.12147. eCollection 2017 Jan.
3
Ligands of Therapeutic Utility for the Liver X Receptors.
肿瘤微环境中的胆固醇代谢:癌症特征与治疗机遇
Int J Biol Sci. 2024 Mar 17;20(6):2044-2071. doi: 10.7150/ijbs.92274. eCollection 2024.
4
Liver X Receptors (LXRs) in cancer-an Eagle's view on molecular insights and therapeutic opportunities.癌症中的肝脏X受体(LXRs)——关于分子见解和治疗机会的全景视角
Front Cell Dev Biol. 2024 Mar 14;12:1386102. doi: 10.3389/fcell.2024.1386102. eCollection 2024.
5
The role of cholesterol metabolism in tumor therapy, from bench to bed.胆固醇代谢在肿瘤治疗中的作用:从实验台到病床
Front Pharmacol. 2023 Apr 6;14:928821. doi: 10.3389/fphar.2023.928821. eCollection 2023.
6
Targeting Nuclear Receptors in Lung Cancer-Novel Therapeutic Prospects.肺癌中靶向核受体——新的治疗前景
Pharmaceuticals (Basel). 2022 May 18;15(5):624. doi: 10.3390/ph15050624.
7
Cholesterol Metabolic Reprogramming in Cancer and Its Pharmacological Modulation as Therapeutic Strategy.癌症中的胆固醇代谢重编程及其作为治疗策略的药理调节
Front Oncol. 2021 May 24;11:682911. doi: 10.3389/fonc.2021.682911. eCollection 2021.
8
Cytoplasmic LXR expression is an independent marker of poor prognosis for patients with early stage primary breast cancer.细胞质 LXR 表达是早期原发性乳腺癌患者预后不良的独立标志物。
J Cancer Res Clin Oncol. 2021 Sep;147(9):2535-2544. doi: 10.1007/s00432-021-03670-y. Epub 2021 Jun 3.
9
Modulation of LXR signaling altered the dynamic activity of human colon adenocarcinoma cancer stem cells in vitro.肝X受体信号的调节改变了人结肠腺癌癌症干细胞在体外的动态活性。
Cancer Cell Int. 2021 Feb 10;21(1):100. doi: 10.1186/s12935-021-01803-4.
10
Bioinformatics analysis and identification of circular RNAs promoting the osteogenic differentiation of human bone marrow mesenchymal stem cells on titanium treated by surface mechanical attrition.表面机械研磨处理钛上促进人骨髓间充质干细胞成骨分化的环状RNA的生物信息学分析与鉴定
PeerJ. 2020 Jul 13;8:e9292. doi: 10.7717/peerj.9292. eCollection 2020.
肝脏X受体的治疗用配体
Molecules. 2017 Jan 5;22(1):88. doi: 10.3390/molecules22010088.
4
Distinct gene regulatory programs define the inhibitory effects of liver X receptors and PPARG on cancer cell proliferation.不同的基因调控程序决定了肝脏X受体和PPARG对癌细胞增殖的抑制作用。
Genome Med. 2016 Jul 11;8(1):74. doi: 10.1186/s13073-016-0328-6.
5
LXR ligands sensitize EGFR-TKI-resistant human lung cancer cells in vitro by inhibiting Akt activation.LXR配体通过抑制Akt激活在体外使EGFR-TKI耐药的人肺癌细胞致敏。
Biochem Biophys Res Commun. 2015 Nov 27;467(4):900-5. doi: 10.1016/j.bbrc.2015.10.047. Epub 2015 Oct 21.
6
AKT inactivation causes persistent drug tolerance to EGFR inhibitors.AKT失活导致对表皮生长因子受体(EGFR)抑制剂产生持续的耐药性。
Pharmacol Res. 2015 Dec;102:132-7. doi: 10.1016/j.phrs.2015.09.022. Epub 2015 Oct 22.
7
Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations.携带EGFR突变的晚期非小细胞肺癌患者接受EGFR-TKI治疗后的进展后生存期
PLoS One. 2015 Aug 11;10(8):e0135393. doi: 10.1371/journal.pone.0135393. eCollection 2015.
8
Current mechanistic insights into the roles of matrix metalloproteinases in tumour invasion and metastasis.目前对基质金属蛋白酶在肿瘤侵袭和转移中作用的机制性见解。
J Pathol. 2015 Nov;237(3):273-81. doi: 10.1002/path.4586. Epub 2015 Sep 10.
9
Global cancer statistics, 2012.全球癌症统计数据,2012 年。
CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4.
10
Molecular spectrum of somatic EGFR and KRAS gene mutations in non small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel variations in Indian patients.非小细胞肺癌中体细胞表皮生长因子受体(EGFR)和 Kirsten 大鼠肉瘤病毒癌基因(KRAS)基因突变的分子谱:印度患者中突变频率、分布模式的测定及新变异的鉴定
Pathol Oncol Res. 2015 Jul;21(3):675-87. doi: 10.1007/s12253-014-9874-7. Epub 2015 Jan 31.